Drug approvals are way up through three quarters, including a number of first-in-class approvals. The first drug targeting a metabolic enzyme mutated in cancer (Celgene's mitochondrial isocitrate dehydrogenase) was approved. The approval of Novartis' highly anticipated CAR-T cancer therapy Kymriah for acute myelogenous leukemia was followed two months later by another: Gilead/Kite's Yescarta for diffuse large B-cell lymphomas. Several gene therapies attained breakthrough drug designation; the first AAV gene therapy approval for a retinal disorder looks likely before year's end.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline 3Q17. Nat Biotechnol 35, 1125 (2017). https://doi.org/10.1038/nbt.4032
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4032